Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
WEBINAR | Join top cancer researchers to explore advances transforming early discovery, from new targets and models to the therapies of tomorrow
news

Bowel cancer medication could help combat early-onset Parkinson’s disease

People with certain forms of early-onset Parkinson’s disease could potentially benefit from taking a medication used to treat certain forms of cancer.

Parkinsons

This is according to new research by University of Leicester scientists. The study suggests that folinic acid, which is used in medications to treat bowel cancer, can also protect neurons associated with Parkinson’s disease in fruit flies.

Dr Miguel Martins from the MRC Toxicology Unit at the University of Leicester explained: “Parkinson’s disease is a disabling disorder for which no cure is yet available; further, after dopaminergic neurons are lost, only a few palliative treatment options for Parkinson’s symptoms are available.

Therefore, treatments that either prevent or delay the onset of the disease at an early stage are needed.

“Folinic acid is already approved and used for applications in the clinic as an adjuvant during chemotherapy and can be administered orally, as a dietary supplement, or intravenously.

 

Reserve your FREE place

 


Are low affinity or poor TCR yields slowing you down?

Explore how CHO expression of soluble TCRs and TCR affinity maturation workflows via phage, serving as essential building blocks for early-stage TCR-TCE candidate generation.

22 October 2025 | 16:00 PM BST | FREE Webinar

Join Jiansheng Wu, Ph.D. to explore two integrated strategies:

  • High-titer CHO-based expression of sTCRs (~100 mg/L), enabling scalable and high-throughput production
  • Optimized phage display affinity maturation, improving TCR binding by up to ~10,000-fold

Whether you’re starting a new TCR program or optimizing an existing platform, this session will offer actionable strategies to accelerate discovery and improve candidate quality.

Register Now – It’s Free!

 

“Thus, the drug safety risk is low, and drug development for repurposing folinic acid as a treatment for Parkinson’s disease would be faster than for a novel drug.

“With this in mind, it seems worthwhile to further test the supplementation of folinic acid in clinical trials with human participants as a potential preventative or palliative therapeutic for PD and to expand the repertoire of treatment options.”

Preclinical model

The researchers studied fruit flies with faulty mitochondria caused by a mutation that mimics Parkinson’s disease in humans. Lab experiments, like this, allow us to draw conclusions about the effect of folinic acid on neurons in fruit flies.

Previous research by the team has shown that folic acid protects neurons in models of Parkinson’s disease. Folinic acid is related to folic acid but is metabolically more active.

In contrast to folic acid, folinic acid taken orally can penetrate into the human brain.

This research was funded by the Medical Research Council.